Cardiac Marker Testing Market to reach 9.7 billion in 2030, at a CAGR of 10.3% | IMR

The Cardiac Marker Testing Market stood at USD 4.8 billion in 2023-e and projected to grow at a CAGR of 10.3% through 2030 to reach USD 9.7 billion. Increasing Prevalence of Cardiovascular Diseases Will Foster the Growth of Cardiac Marker Testing Market

The rising prevalence of cardiovascular diseases, coupled with technological advancements and an aging population, drives the cardiac biomarker testing market. Opportunities lie in point-of-care testing, enhancing accessibility, and ongoing investments in biomarker research and development, promising refined diagnostics. The intersection of these drivers and opportunities foretells a future where efficient, precise, and accessible cardiac testing plays a pivotal role in managing and mitigating the impact of cardiovascular diseases.

The integration of telemedicine and remote monitoring with cardiac biomarker testing transforms cardiovascular healthcare. Patients remotely access healthcare professionals via telemedicine for consultations and guidance based on biomarker data. Real-time monitoring facilitates proactive interventions, enhancing accessibility for patients to undergo testing from home. This seamless integration signifies a paradigm shift towards patient-centric, remote cardiovascular care, optimizing diagnostics and supporting timely interventions.

Instruments segment to register significant growth over the forecast period of 2024-2030. Cardiac marker testing instruments encompass diverse technologies, including ELISA, chemiluminescence, immunofluorescence, immunochromatography, and other innovative methods. These instruments play a pivotal role in accurately measuring cardiac biomarkers, contributing to advancements in cardiovascular diagnostics. This diversity in instrument types ensures flexibility and accuracy in cardiovascular diagnostics, catering to the varied requirements of clinical laboratories and healthcare facilities.

In cardiac marker testing at POCT facilities, rapid on-site diagnostics for cardiovascular conditions are conducted using portable testing devices. This enables immediate results at the bedside or in outpatient settings, particularly for markers such as Troponins. Designed for simplicity and speed, these tests are suitable for decentralized healthcare settings such as emergency departments, ambulances, or clinics, facilitating timely interventions and improving patient outcomes.

The growth of the North American market is attributed to several factors, including the strong presence of major industry players in the region. Furthermore, cardiovascular disease remains the leading cause of mortality across genders and ethnicities in the US. A staggering statistic highlights the reality, with one person succumbing to cardiovascular disease every 33 seconds, contributing to approximately 695,000 deaths in the country in 2021.

The cardiac marker testing market is characterized by the presence of various small and big players. The major market players include Abbott, Becton, Dickinson and Company, bioMérieux, Bio-Rad, Danaher, DiaSorin, LSI Medience, PerkinElmer, Quidel, Roche, Siemens, Thermo Fisher Scientific, and Tosoh, amongst others.  In a competitive market landscape, players are swiftly embracing advanced technologies to enhance cardiac marker testing operations and bolster their competitive stance through strategic initiatives, including mergers, acquisitions, and the introduction of new products.